Flag of the European Union EU Clinical Trials Register Help

Clinical trials for roche OR chugai OR genentech

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,190 result(s) found for: roche OR chugai OR genentech. Displaying page 148 of 160.
    «« First « Previous 144  145  146  147  148  149  150  151  152  Next» Last»»
    EudraCT Number: 2013-004679-11 Sponsor Protocol Number: B3271004 Start Date*: 2014-07-22
    Sponsor Name:Pfizer Inc
    Full Title: A Randomized, Double-blind Pharmacokinetic Study of PF-05280014 Plus Taxotere and Carboplatin Versus Herceptin Plus Taxotere And Carboplatin For The Neoadjuvant Treatment Of Patients With Operable ...
    Medical condition: HER2-Positive Breast Cancer (Early Stage)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10006194 Breast cancer NOS stage I LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) SK (Completed) CZ (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005141-32 Sponsor Protocol Number: MYL-1402O-3001 Start Date*: 2016-07-11
    Sponsor Name:Mylan GmbH
    Full Title: Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous...
    Medical condition: Stage IV unresectable, recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) HR (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003810-13 Sponsor Protocol Number: 000289 Start Date*: 2018-05-21
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group, dose-range trial to investigate the efficacy and safety of FE 999302 as add-on treatment to follitropin delta (REKOVELLE) in women un...
    Medical condition: Women diagnosed with tubal infertility or unexplained infertility or endometriosis stage I/II or having partners diagnosed with male factor infertility, eligible for IVF and/or ICSI.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004872 10021940 Infertility, female, of unspecified origin LLT
    21.0 100000004872 10016403 Female infertility of tubal origin LLT
    21.1 100000004872 10025511 Male infertility, unspecified LLT
    21.0 100000004872 10014787 Endometriosis of uterus LLT
    21.0 100000004872 10014784 Endometriosis of ovary LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) DK (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004505-27 Sponsor Protocol Number: DZB-CS-202 Start Date*: 2020-07-09
    Sponsor Name:Basilea Pharmaceutica International Ltd.
    Full Title: A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic a...
    Medical condition: HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) FR (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005758-36 Sponsor Protocol Number: UTX-TGR-304 Start Date*: 2016-10-28
    Sponsor Name:TG Therapeutics
    Full Title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chr...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000698-22 Sponsor Protocol Number: MK-7339-003 Start Date*: 2020-02-26
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with a Fluoropyrimidine in Participants with ...
    Medical condition: The treatment of participants with unresectable or metastatic CRC that has not progressed following an induction course of FOLFOX + bevacizumab
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) FR (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-001008-14 Sponsor Protocol Number: AT148006 Start Date*: 2021-10-25
    Sponsor Name: ALX Oncology Inc.
    Full Title: A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma
    Medical condition: Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10017770 Gastric carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003946-36 Sponsor Protocol Number: TAK-981-1501 Start Date*: 2022-10-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
    Medical condition: Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004758-40 Sponsor Protocol Number: GCT1015-05/ENGOT-cx8 Start Date*: 2019-02-22
    Sponsor Name:Genmab A/S
    Full Title: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
    Medical condition: recurrent or stage IVB cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003427-38 Sponsor Protocol Number: MOTIVATE Start Date*: 2020-03-12
    Sponsor Name:HZRM – Hämophilie-Zentrum Rhein Main GmbH
    Full Title: MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial
    Medical condition: Inhibitor-Positive patients with Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013483-38 Sponsor Protocol Number: CC-5013-DLC-001 Start Date*: 2010-07-20
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2/3 MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARG...
    Medical condition: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) AT (Completed) GB (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003313-17 Sponsor Protocol Number: GS-US-312-0123 Start Date*: 2014-06-04
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lympho...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) BE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) ES (Completed) PL (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002917-38 Sponsor Protocol Number: SG040-0005 Start Date*: 2008-02-20
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A Randomised, Phase IIb Placebo-controlled Study of R-ICE Chemotherapy (Rituximab, Isofosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Se...
    Medical condition: Diffuse Large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Prematurely Ended) BE (Completed) HU (Completed) FR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000219-27 Sponsor Protocol Number: 3129K4-3301-WW Start Date*: 2008-04-25
    Sponsor Name:Wyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company
    Full Title: An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed ...
    Medical condition: Relapsed or refractory, CD22-Positive, follicular B-cell Non Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029473 Nodular (follicular) lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) PT (Prematurely Ended) DE (Completed) FR (Completed) GB (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003940-30 Sponsor Protocol Number: NO21157 Start Date*: 2008-05-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarc...
    Medical condition: Ewing’s sarcoma and other sarcoma subtypes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015560 Ewing's sarcoma LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011786-80 Sponsor Protocol Number: 526H04 Start Date*: 2010-06-15
    Sponsor Name:ZymoGenetics, Inc.
    Full Title: Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus Infection
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) CZ (Completed) AT (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004720-35 Sponsor Protocol Number: NORD-STAR Start Date*: 2012-05-28
    Sponsor Name:The Karolinska Institute, ClinTRID
    Full Title: A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two d...
    Medical condition: Rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IS (Trial now transitioned) DK (Trial now transitioned) FI (Completed) NO (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004027-52 Sponsor Protocol Number: GINECO-OV125b Start Date*: 2015-11-30
    Sponsor Name:ARCAGY Research
    Full Title: Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer trea...
    Medical condition: Patients with advanced FIGO stage IIIB – IV high grade epithelial ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing) AT (Completed) BE (Completed) ES (Ongoing) DK (Completed) SE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005189-39 Sponsor Protocol Number: 11-10 Start Date*: 2012-01-11
    Sponsor Name:Cancer Trials Ireland
    Full Title: TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer.
    Medical condition: HER2-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed) DE (Completed) FI (Completed) PT (Completed) ES (Temporarily Halted) IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-003314-13 Sponsor Protocol Number: P1200_11 Start Date*: 2013-03-25
    Sponsor Name:Cliniques Universitaires Saint Luc, Université catholique de Louvain
    Full Title: RING – RItuximab for lupus Nephritis with remission as a Goal, an investigator-initiated randomized international open multicentric study
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SE (Ongoing) AT (Completed) PT (Completed) ES (Ongoing) DE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 144  145  146  147  148  149  150  151  152  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 05:39:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA